Group 1 - The company announced a capital increase agreement approved by the board on May 28, 2025, involving investments of RMB 150 million, RMB 130 million, and RMB 20 million from the company, Guangzhou Pharmaceutical Venture Capital Fund, and Guangzhou Old Brand Fund respectively [1] - After the capital increase, the registered capital of Baiyunshan Biological will rise from RMB 84 million to RMB 121 million, while the company's direct and indirect shareholding will remain unchanged at 50% [1] - Baiyunshan Biological is a significant subsidiary of the company, primarily engaged in the research, production, and sales of human rabies vaccines (Vero cells), which is crucial for the company's innovation-driven development strategy [2] Group 2 - The capital increase aims to address the funding needs of Baiyunshan Biological, facilitating the application for production licenses for new products and supporting the development of the company's biopharmaceutical business [2] - Baiyunshan Biological's financial performance will continue to be included in the company's consolidated financial statements [1][2]